Jupiter Neurosciences (NASDAQ:JUNS) Issues Earnings Results, Misses Estimates By $5.01 EPS

Jupiter Neurosciences (NASDAQ:JUNS) announced its quarterly earnings data on Friday. The company reported ($5.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($5.01), Zacks reports. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.40 million.

Jupiter Neurosciences Trading Down 12.7%

JUNS traded down $0.76 on Friday, hitting $5.24. 105,488 shares of the company’s stock traded hands, compared to its average volume of 318,208. The company’s 50 day simple moving average is $12.93 and its 200-day simple moving average is $25.41. Jupiter Neurosciences has a one year low of $4.56 and a one year high of $137.96. The firm has a market cap of $4.03 million, a price-to-earnings ratio of -0.27 and a beta of 1.98.

Analyst Ratings Changes

A number of analysts recently commented on JUNS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. Wall Street Zen raised Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Hedge funds have recently bought and sold shares of the stock. Vestor Capital LLC lifted its position in Jupiter Neurosciences by 144,607.2% during the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the last quarter. Yorkville Advisors Global LP bought a new stake in shares of Jupiter Neurosciences in the 4th quarter worth about $135,000. Geode Capital Management LLC raised its position in shares of Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after buying an additional 28,826 shares in the last quarter. Finally, Allen Capital Group LLC purchased a new stake in shares of Jupiter Neurosciences during the 4th quarter valued at about $31,000.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.